– USA, FL – Lumos Diagnostics today announced the expansion of its board with the appointments of Bronwyn Le Grice, Larry Mehren, and Catherine Robson to its Board as independent directors. They will join Executive Chair Sam Lanyon and Executive Director Dr. Rob Sambursky and will support the continued growth of the rapid point-of-care diagnostic products and services business.
“On behalf of the entire company, I am delighted to welcome Bronwyn, Larry and Catherine to the Lumos Board of Directors,” said Executive Chair, Sam Lanyon. “Together, they offer extensive and diverse operational experience in growing diagnostic companies, strong knowledge of equity markets and broad corporate governance expertise. Lumos will benefit from their guidance as we expand our commercial infrastructure and global market access to novel point-of-care tests.”
About Bronwyn Le Grice
Bronwyn Le Grice brings expertise in digital health and public market knowledge. She has more than eighteen years of executive experience in the health technology sector including venture capital, corporate development, and industry advocacy. In 2017, Ms. Le Grice founded ANDHealth, Australia’s only dedicated digital health accelerator and commercialization support organization.
About Lawrence Mehren
Larry Mehren provides diagnostic operational proficiency and public market experience. He served as the Chief Executive Officer and a Director of Accelerate Diagnostics (Nasdaq AXDX) from 2012 to 2020. Before this, Mr. Mehren served as Senior Vice President and Chief Financial Officer of Ventana Medical Systems, Inc. from 2007 until 2008 and as Head of Global Business from 2008 until 2011.
About Catherine Robson
Catherine Robson expands Lumos’ financial capabilities and corporate governance experience. Catherine founded Affinity Private, a financial services firm, and has non-executive director experience at Greater Bank, SCALE Investors, and on ASX-listed Equity Trust Limited Holdings Limited. She was previously a member of both the EQT Board Risk Committee and the Board Remuneration, Human Resources, and Nominations Committee.
About Sam Lanyon
Lumos Board Executive Chair Sam Lanyon has more than twenty-five years of experience in business strategy, executive sales, and operational management with a demonstrated track record in the global commercialization of technology-rich healthcare products. He also serves as Co-CEO and co-founder of Planet Innovation.
About Dr. Rob Sambursky
Executive Director Rob Sambursky, MD, is one of the founders and former executives of RPS Diagnostics, which merged with Lumos Diagnostics in 2019, and currently leads Lumos as its President and Chief Executive Officer. In addition to his product development and commercial experience, he has a strong scientific and clinical background in medical sciences, ophthalmology, and infectious disease.
About Lumos Diagnostics
Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel, Lumos-branded POC tests that target infectious and inflammatory diseases with unmet diagnostic needs.
For more information: https://lumosdiagnostics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
